Ken Griffin’s Janux Therapeutics JANX Stock Holding History

Ken Griffin’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$680K	Buy	48,900 +1,400	+3%	+$19.2K	﹤0.01%	8552
2025 Q4	$656K	Buy	47,500 +34,900	+277%	+$821K	﹤0.01%	8361
2025 Q3	$308K	Buy	+12,600	New	+$307K	﹤0.01%	10308
2025 Q2	–	Sell	-26,000	Closed	-$702K	–	13821
2025 Q1	$702K	Buy	26,000 +18,100	+229%	+$682K	﹤0.01%	7741
2024 Q4	$423K	Buy	7,900 +2,600	+49%	+$138K	﹤0.01%	8930
2024 Q3	$241K	Buy	5,300 +3,500	+194%	+$152K	﹤0.01%	9764
2024 Q2	$75.4K	Sell	1,800 -11,800	-87%	-$554K	﹤0.01%	11278
2024 Q1	$512K	Buy	13,600 +8,000	+143%	+$174K	﹤0.01%	8344
2023 Q4	$60.1K	Buy	5,600 +3,200	+133%	+$27.7K	﹤0.01%	11591
2023 Q3	$24.2K	Sell	2,400 -14,500	-86%	-$167K	﹤0.01%	12469
2023 Q2	$201K	Sell	16,900 -35,200	-68%	-$470K	﹤0.01%	9884
2023 Q1	$630K	Sell	52,100 -7,900	-13%	-$131K	﹤0.01%	7824
2022 Q4	$790K	Buy	+60,000	New	+$878K	﹤0.01%	7283

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ken Griffin's JANX Position: Q1 2026 in Review

Ken Griffin reduced its Janux Therapeutics (JANX) stake by 68% in Q1 2026, selling an estimated $10.3M and leaving 352,177 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4370.

Ken Griffin first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $88.5M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Ken Griffin held 352,177 shares of Janux Therapeutics worth $4.9M as of Q1 2026.
Ken Griffin sold 751,967 Janux Therapeutics shares in Q1 2026, an estimated $10.3M.
Janux Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4370 holding.
Ken Griffin first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
Ken Griffin's Janux Therapeutics position peaked at $88.5M in Q1 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.